Group (mg/kg) DAI of the 7th day Colon weight/length (mg/cm) Normal 0 25.91[+ or -]1.92 control DSS control 2.59[+ or -]0.18 38.44[+ or -]2.84 (a) (a) Sulfasalazine
0.78[+ or -]0.13 28.76[+ or -]2.06 (a), (b) (500) (a), (b) HES (10) 1.58[+ or -]0.21 31.72[+ or -]1.86 (a), (b), (a), (b), (c) (c) HES (40) 1.12[+ or -]0.09 30.63[+ or -]1.98 (a), (b) (a), (b), (c) HES (80) 1.00[+ or -]0.05 29.78[+ or -]0.99 (a), (b) (a), (b), (c) Values are expressed as mean [+ or -] SEM.
Study Medication and Dosage: All patients were given either sulfasalazine
(1.0-3.0 g/day; median 2.0 g/day) or mesalamine (1.5-3.0 g/day; median 2.25 g/day).
For the active substance sulfasalazine
, The aok rheinland-pfalz / saarland - die gesundheitskasse offers discount agreements to all interested pharmaceutical companies for the period up to the entry into force of exclusive contracts following a formal award procedure in accordance with the regulations of part 4 of the gwb.
The use of anti-TNF-[alpha] agents is preferred for patients who are refractory to treatment with NSAIDs and sulfasalazine
Historically, medications used to treat PsA have included nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate, sulfasalazine
, and leflunomide.
* Immediate triple DMARD therapy with methotrexate, sulfasalazine
, and hydroxychloroquine.
At the end of 12 months, 105 of the 128 patients in the infliximab-plus-methotrexate group and 89 of the 130 patients in the sulfasalazine
/ hydroxy-chloroquine-plus-methotrexate group remained on their allocated treatment.
Similarly, systemic lupus erythematosus (SLE) patients also have been reported as a result of sulfasalazine
The study compared reduction in joint swelling among 121 people with RA who took either the herb or an anti-inflammatory drug, sulfasalazine
The EULAR recommendations make methotrexate the lone top agent, placing leflunomide along with sulfasalazine
and injectable gold as the top DMARD options for patients who are intolerant of or have contraindications for methotrexate.
Combination therapy with methotrexate, sulfasalazine
, and hydroxychloroquine plus prednisone has previously been shown to be associated with a remission rate of 37% in patients with early RA, Dr.
The synthetic DMARDs include azathioprine (Imuran), cyclosporine (Sandimmune, Neoral), gold compounds, hydroxychloroquine (Plaquenil), leflunomide (Arava), methotrexate, penicillamine, and sulfasalazine